American Society of Hirudotherapy

NrlHM2

Second macin-family antimicrobial peptide candidate from Hirudo medicinalis (Serebrennikova 2025) — paralog of NrlHM1.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 27, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • NrlHM28.5 kDa
Molecular weight (kilodaltons) of NrlHM2 (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
In vitro
Drug vs leech
Recombinant (genetically expressed)
Safety domains
Antibiotic stewardship

Clinical translation limit

NrlHM2's in vitro antibacterial activity does NOT establish clinical efficacy. No FDA-approved derivative exists; functional differentiation from NrlHM1 remains undefined.

Molecular Profile

Category
Antimicrobial
Evidence tier
Preclinical
Molecular weight
8,500 Da
Source species
Hirudo medicinalis
Discovered
2025 · Serebrennikova M et al.

Biological Targets

  • → Gram-positive bacteria (laboratory strains)

Key Citations

  1. Serebrennikova M et al. (2025), Int J Mol Sci · PMID 40725149

External Resources

    Related Antimicrobial Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.